Michael Patrick Collins
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Michael Patrick Collins has a total of 313 co-authors. Here are the top co-authors by number of shared publications:
- Alexis Khalil
Foghorn Therapeutics Inc.; Watertown, MA, USA
49 shared publications - Alfonso Quintás-Cardama
Foghorn Therapeutics Inc.; Watertown, MA, USA
49 shared publications - Denice Hickman
Foghorn Therapeutics Inc., Cambridge, Massachusetts
48 shared publications - Jessica Piel
Foghorn Therapeutics Inc., Cambridge, Massachusetts
48 shared publications - Kathleen Healy
Foghorn Therapeutics Inc., Cambridge, Massachusetts
48 shared publications - Kim Horrigan
Foghorn Therapeutics Inc., Cambridge, Massachusetts
48 shared publications
Latest Publications
- 4 June 2026
- Published by American Society of Hematology in Blood
- Vol. 147 (23) , 2809-2820
Overcoming menin inhibitor resistance in AML cells with combinations including BET proteins and a dual BRG1/BRM inhibitor
Menin inhibitors (MI) disrupt the binding of menin to mixed-lineage leukemia 1 (MLL1), leading to the repression of MLL1 or MLL1-fusion protein target genes, including reduced levels of HOXA9 and MEIS1 in acute myeloid leukemia (AML) with mutant NPM1 (mtNPM1) or MLL1 rearrangement (MLL1-r). Although MI are relatively well tolerated and induce clinical remissions, they are often short-lived due to the development of resistance followed by AML relapse. Through repeated shocks with the MI SNDX-50469, a precursor tool compound to revumenib, followed by recovery, we developed MI-resistant (MITR) AML MV4-11 and OCI-AML3 cells. Present studies show that compared with MI-sensitive parental cells, MITR cells exhibit an altered epigenome, transcriptome, and proteome, without menin mutations. Through a CRISPR screen, novel druggable MI coenrichments were identified and targeted, including BRD4, SMARCA4, and CREBBP. Cotreatment with the MI and the SMARCA4/SMARCA2 (BRG1/BRM) inhibitor FHD-286 or the BET proteins inhibitor OTX015 (birabresib) synergistically induced in vitro lethality in MITR and MI-resistant AML cells expressing the mutant menin (M327I), as well as in patient-derived (PD) AML cells with MLL1-r or mtNPM1 that exhibited ex vivo resistance to MI. Compared with each drug alone, cotreatment with SNDX-5613 (revumenib) and FHD-286 or OTX015 and FHD-286 significantly reduced the in vivo AML burden and improved survival of the immune-depleted mice, without inducing significant toxicity, in the xenograft models of MITR and MI-resistant PD MLL1-r AML cells. These findings highlight novel, targeted, drug combinations that overcome MI resistance in AML cells with MLL1-r or mtNPM1.
- 4 June 2026
- Published by American Society of Hematology in Blood
- Vol. 147 (23) , 2809-2820
Overcoming menin inhibitor resistance in AML cells with combinations including BET proteins and a dual BRG1/BRM inhibitor
Menin inhibitors (MI) disrupt the binding of menin to mixed-lineage leukemia 1 (MLL1), leading to the repression of MLL1 or MLL1-fusion protein target genes, including reduced levels of HOXA9 and MEIS1 in acute myeloid leukemia (AML) with mutant NPM1 (mtNPM1) or MLL1 rearrangement (MLL1-r). Although MI are relatively well tolerated and induce clinical remissions, they are often short-lived due to the development of resistance followed by AML relapse. Through repeated shocks with the MI SNDX-50469, a precursor tool compound to revumenib, followed by recovery, we developed MI-resistant (MITR) AML MV4-11 and OCI-AML3 cells. Present studies show that compared with MI-sensitive parental cells, MITR cells exhibit an altered epigenome, transcriptome, and proteome, without menin mutations. Through a CRISPR screen, novel druggable MI coenrichments were identified and targeted, including BRD4, SMARCA4, and CREBBP. Cotreatment with the MI and the SMARCA4/SMARCA2 (BRG1/BRM) inhibitor FHD-286 or the BET proteins inhibitor OTX015 (birabresib) synergistically induced in vitro lethality in MITR and MI-resistant AML cells expressing the mutant menin (M327I), as well as in patient-derived (PD) AML cells with MLL1-r or mtNPM1 that exhibited ex vivo resistance to MI. Compared with each drug alone, cotreatment with SNDX-5613 (revumenib) and FHD-286 or OTX015 and FHD-286 significantly reduced the in vivo AML burden and improved survival of the immune-depleted mice, without inducing significant toxicity, in the xenograft models of MITR and MI-resistant PD MLL1-r AML cells. These findings highlight novel, targeted, drug combinations that overcome MI resistance in AML cells with MLL1-r or mtNPM1.
- Open Access
- 12 December 2025
- Published by Wiley in Cancer Medicine
- Vol. 14 (24) , e71442
Prognostic Implications of SMARCA4 , ARID1A , and Other BAF Mutations in Non‐Small Cell Lung Cancer
Background and Methods: Non‐small cell lung cancer (NSCLC) outcomes have improved remarkably with the widespread use of immune checkpoint inhibitors and small molecule inhibitors targeting driver mutations. Nevertheless, many patients continue to experience suboptimal outcomes. The prevalence of mutations in the BAF (BRG1/BRM‐associated factor) chromatin remodeling complexes may represent an opportunity to help close this gap: These critical regulators of chromatin accessibility are mutated in approximately a quarter of NSCLC cases, and numerous retrospective reports have evaluated the impact of these mutations on clinical outcomes. Here, we appraise the varying and occasionally divergent evidence for BAF complex mutations as predictive and prognostic biomarkers in NSCLC. Results: We conclude that these mutations hold promise as refinements to existing prognostic and treatment algorithms, with SMARCA4 mutations imparting poor prognosis, ARID1A mutations predicting better prognosis with immune checkpoint inhibitor therapy, and ARID1A ‐epithelial growth factor receptor ( EGFR ) comutations being associated with insensitivity to EGFR tyrosine kinase inhibitor therapy. Additional research should focus on large, prospective studies that will allow better quantification of the impact of BAF complex mutations. Conclusions: A growing body of evidence indicates that BAF complex mutations have important prognostic implications. These may be leveraged for risk stratification and therapeutic selection in patients with non‐small cell lung cancer.
- 12 December 2025
- Published by Wiley in Cancer Medicine
- Vol. 14 (24) , e71442
Open AccessPrognostic Implications of SMARCA4 , ARID1A , and Other BAF Mutations in Non‐Small Cell Lung Cancer
Background and Methods: Non‐small cell lung cancer (NSCLC) outcomes have improved remarkably with the widespread use of immune checkpoint inhibitors and small molecule inhibitors targeting driver mutations. Nevertheless, many patients continue to experience suboptimal outcomes. The prevalence of mutations in the BAF (BRG1/BRM‐associated factor) chromatin remodeling complexes may represent an opportunity to help close this gap: These critical regulators of chromatin accessibility are mutated in approximately a quarter of NSCLC cases, and numerous retrospective reports have evaluated the impact of these mutations on clinical outcomes. Here, we appraise the varying and occasionally divergent evidence for BAF complex mutations as predictive and prognostic biomarkers in NSCLC. Results: We conclude that these mutations hold promise as refinements to existing prognostic and treatment algorithms, with SMARCA4 mutations imparting poor prognosis, ARID1A mutations predicting better prognosis with immune checkpoint inhibitor therapy, and ARID1A ‐epithelial growth factor receptor ( EGFR ) comutations being associated with insensitivity to EGFR tyrosine kinase inhibitor therapy. Additional research should focus on large, prospective studies that will allow better quantification of the impact of BAF complex mutations. Conclusions: A growing body of evidence indicates that BAF complex mutations have important prognostic implications. These may be leveraged for risk stratification and therapeutic selection in patients with non‐small cell lung cancer.
- Open Access
- 13 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Supplementary Figure 5. Blast percentage, hemoglobin level, leukocyte count, neutrophil count, platelet count over time, and total daily dose exposure for patient 39; R/R AML; FHD-286 7.5 mg QD dose group.
- 13 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Supplementary Figure 5. Blast percentage, hemoglobin level, leukocyte count, neutrophil count, platelet count over time, and total daily dose exposure for patient 39; R/R AML; FHD-286 7.5 mg QD dose group.
- Open Access
- 13 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 6 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Supplementary Table 6. FHD-286 induced myeloid differentiation. Genetic and mutational profiles of patients for whom matched bone marrow samples at screening and on FHD-286 were analyzed.
- 13 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 6 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Supplementary Table 6. FHD-286 induced myeloid differentiation. Genetic and mutational profiles of patients for whom matched bone marrow samples at screening and on FHD-286 were analyzed.
- Open Access
- 13 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 8 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Supplementary Figure 8. Blast percentage, hemoglobin level, leukocyte count, neutrophil count, platelet count over time, and total daily dose exposure for patient 15; R/R AML; FHD-286 10 mg QD dose group.
- 13 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 8 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Supplementary Figure 8. Blast percentage, hemoglobin level, leukocyte count, neutrophil count, platelet count over time, and total daily dose exposure for patient 15; R/R AML; FHD-286 10 mg QD dose group.
- Open Access
- 13 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 10 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Supplementary Figure 10. Bone marrow blasts, peripheral blasts, and absolute neutrophil counts over time in patients with >50% reduction in bone marrow blasts from baseline, by parameter.
- 13 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 10 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Supplementary Figure 10. Bone marrow blasts, peripheral blasts, and absolute neutrophil counts over time in patients with >50% reduction in bone marrow blasts from baseline, by parameter.
- Open Access
- 13 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Supplementary Figure 3. Blast percentage, hemoglobin level, leukocyte count, neutrophil count, platelet count over time, and total daily dose exposure for patient 29; R/R AML; 5 mg QD dose group.
- 13 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Supplementary Figure 3. Blast percentage, hemoglobin level, leukocyte count, neutrophil count, platelet count over time, and total daily dose exposure for patient 29; R/R AML; 5 mg QD dose group.
- Open Access
- 13 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 9 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Supplementary Figure 9. Bone marrow blasts, peripheral blasts, and absolute neutrophil counts over time in patients with >50% reduction in bone marrow blasts from baseline, by patient.
- 13 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 9 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Supplementary Figure 9. Bone marrow blasts, peripheral blasts, and absolute neutrophil counts over time in patients with >50% reduction in bone marrow blasts from baseline, by patient.
- Open Access
- 13 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 7 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Supplementary Figure 7. Blast percentage, hemoglobin level, leukocyte count, neutrophil count, platelet count over time, and total daily dose exposure for patient 13; R/R AML; FHD-186 10 mg QD dose group.
- 13 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 7 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Supplementary Figure 7. Blast percentage, hemoglobin level, leukocyte count, neutrophil count, platelet count over time, and total daily dose exposure for patient 13; R/R AML; FHD-186 10 mg QD dose group.
- Open Access
- 13 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 14 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Supplementary Figure 14. Single-cell genomic data set characteristics. A) Dot plot showing expression of key cell type-specific marker genes.
- 13 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 14 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Supplementary Figure 14. Single-cell genomic data set characteristics. A) Dot plot showing expression of key cell type-specific marker genes.